electroCore Reorganizes its Management Team

electroCore LLC has reshuffled its management team.

Former Chief Operating Officer (COO) Frank Amato is now CEO while co-founder and former CEO JP Errico is assuming the role of chief science and strategy officer. The change is part of a management-proposed development plan, unanimously approved by the company’s board, that is intended to position the company for its next phase of growth.

This will include the commercialization of its gammaCore nVNS therapy for the treatment of cluster headache and migraine. It will also position other key personnel within the company to continue the development of nVNS for the treatment other central nervous system disorders.

Learn more about the gammaCore device by watching the video below:



Amato, who joined electroCore in 2012 as COO, has extensive commercial experience in the pharmaceutical industry, most recently holding the position of U.S. vice president, Specialty Commercial Operations Group, at Merck. Prior to his tenure at Merck, Amato worked at Schering-Plough as executive director of global business operations. Other senior positions he has held include business unit lead, Oncology, for Ligand Pharmaceutical; and national accounts director of Specialty Managed Markets for Pfizer.

Errico, a board member, will focus on leading the team that will spearhead the development of nVNS into other therapeutic areas in the CNS and beyond. Errico, who co-founded electroCore in 2005, has been involved with successfully establishing several prior successful medical ventures, with licenses and sales of technologies and companies in medtech, including co-founding K2 Medical and SpineCore, where he served as CEO and a board member from 2001 to 2004, when it was sold to Stryker Corp. Products patented, developed, and commercialized by the companies he founded have generated more than $12 billion in sales to date. The commercialization of the CE-marked gammaCore therapy has started in Europe through a partnering agreement with Desitin, a CNS-focused specialty pharmaceutical company calling on neurologists and pain doctors treating headache disorders in Germany.

ElectroCore has regulatory approval for the use of gammaCore therapy in the acute and/or prophylactic treatment of cluster headache, migraine and medication overuse headache throughout the European Union. In the United States, it is presently being reviewed by the U.S. Food and Drug Administration for the treatment of cluster headache.

electroCore LLC, the Merck-backed developer of non-invasive vagus nerve stimulation (nVNS) therapy, is focused on treating multiple conditions in the neurology, psychiatry, inflammatory and metabolic disease sectors. The Basking Ridge, N.J.-based company’s initial target is the treatment of primary headaches (migraine and cluster headache), and the associated chronic functional co-morbidities of mood, pain, and sleep, that drive disproportionately large direct and indirect costs within the healthcare system and society.